In the past year, better outcome predictors, studies to define the role of bisphosphonates, and investigations into the use of new chemotherapeutic agents and combinations have advanced the management of multiple myeloma, one of the more common primary tumors of bone. In addition to clinical ...
The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.
tumor heterogeneity, tumor microenvironment, therapeutic resistance in MM, which offers a profound opportunity to improve the diagnosis and identify biomarkers for precision medicine of MM. SCS: single-cell sequencing; MM: multiple myeloma; MGUS: monoclonal...
have insufficient antigen presentation cells, have T cell activation disorders, and other factors that can promote the survival of myeloma cells within the host [6]. With the continuous
The purpose of the present review was to compile and clarify the existing data on the effect of vaccines on the immune system of patients diagnosed with multiple myeloma (MM) and the clinical recommendations for appropriate administration of vaccines. Access through your organization Check access to...
Killmann, N M-BPubMedLeukemia Official Journal of the Leukemia Society of America Leukemia Research Fund U KS VRajkumar, N M-BKillmann. (2009) Spotlight review series on multiple myeloma. Leukemia 23 , R1-R2 /S V, RajkumarN M-B, Killmann. (2009) Spotlight review series on multiple ...
The Multiple Myeloma Hub spoke to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What is the impact of bela... Multiple Myeloma spotlight: Latest survival and efficacy data from the phase III DREAMM-7 trial ...
RADAR (UK-MRA Myeloma XV) Risk-adapted therapy directed according to response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE) https://www.isrctn.com/ISRCTN46841867, Accessed 21st Aug 2023 Googl...
Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation of malignant plasma cells. Despite extensive research, molecular mechanisms in MM that drive drug sensitivity and clinic outcome remain elusive. Single-cell RNA seq
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann Hematol. 2018;97:925–44. CAS PubMed Google Scholar Basler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances...